BEMCENTINIB PRE-CLINICAL COVID-19 DATA PRESENTED AT VIRTUAL IMMUNOLOGY 2021
Bergen, Norway, 11 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that pre-clinical COVID-19 data has been presented at Virtual Immunology 2021, which is taking place from 10-15 May 2021. The poster presentation illustrates findings from a pre-clinical study conducted by BerGenBio’s scientific collaborator Professor Wendy Maury, Professor of Microbiology and Immunology at the University of Iowa. Data from the study provides evidence that SARS-CoV-2